MDACC Study No:2005-0222 ( NCT No: Not Applicable Clinical Trial)
Title:ACROSTUDY – A Multicenter, Post Marketing Surveillance Study of Somavert Therapy in Patients with Acromegaly in the US and Europe
Principal Investigator:Camilo Jimenez
Treatment Agent:Pegvisomat
Study Status:Open
Study Description:The goal of this clinical research study is to look at the safety and
effectiveness of long-term pegvisomant treatment for acromegaly.
Hide details for General InformationGeneral Information

Disease Group:Endocrine
Phase of Study:Phase IV
Treatment Agents:Pegvisomat
Treatment Location:Independent Multicenter Arrangements
Estimated Length of Stay in Houston:N/A
Supported By:N/A
Return Visit:Will be Standard of Care -every 2-3 months until response established (IGF-1
normalizes) and then every 6 months
Home Care:Pegvisomant is administered by the patient daily as a subcutaneous injection.

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Camilo Jimenez
Dept:Endocrine Neoplasia & Hormonal Disorders
For Clinical Trial Enrollment:713-792-2840
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults